Last reviewed · How we verify

ALGRX 3268 — Competitive Intelligence Brief

ALGRX 3268 (ALGRX 3268) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microbiome modulator. Area: Gastroenterology / Immunology.

phase 3 Microbiome modulator Alginate lyase Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ALGRX 3268 (ALGRX 3268) — AlgoRx Pharmaceuticals. ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALGRX 3268 TARGET ALGRX 3268 AlgoRx Pharmaceuticals phase 3 Microbiome modulator Alginate lyase
QA108 granules QA108 granules Smilebiotek Zhuhai Limited phase 3 Gut microbiome modulator
RP-G28 RP-G28 Ritter Pharmaceuticals, Inc. phase 3 Microbiome modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microbiome modulator class)

  1. AlgoRx Pharmaceuticals · 1 drug in this class
  2. Ritter Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALGRX 3268 — Competitive Intelligence Brief. https://druglandscape.com/ci/algrx-3268. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: